24/7 Market News Snapshot 04 February, 2025 – GlucoTrack, Inc. Common Stock (NASDAQ:GCTK)

February 4, 2025

DENVER, Colo., 04 February, 2025 (247marketnews.com) – (NASDAQ:GCTK) are discussed in this article.
GlucoTrack, Inc. (GCTK) is generating significant excitement in the market, currently trading at $1.500, reflecting an impressive increase of 31.58% from the previous day’s close of $1.140. This upward momentum, underscored by a trading volume of 2.32 million shares, highlights enhanced investor confidence in GlucoTrack’s innovative advancements in diabetes care.

A pivotal moment for the company has been the successful completion of its inaugural human clinical study for a groundbreaking Continuous Blood Glucose Monitor (CBGM), designed to be implanted in the subclavian vein. The study, conducted over four days, assessed the safety and procedural aspects related to the placement, use, and removal of the sensor lead. Participants, all diagnosed with diabetes and needing stringent glucose management, reported no serious adverse events linked to the device during its use and the seven-day post-removal phase.

Paul V. Goode, PhD, President & CEO of GlucoTrack, expressed enthusiasm about the study’s outcomes, emphasizing that these results validate the device’s safety and enhance the company’s mission to provide innovative, continuous glucose monitoring solutions. The CBGM aims to revolutionize diabetes management with its long-term implantation feature and an operational lifespan of three years, eliminating the need for external components and minimizing calibration requirements.

Experts like Dr. David Klonoff have recognized the potential of this technology to transform how diabetes is managed. The successful completion of this study positions GlucoTrack on a promising path as it prepares to launch long-term clinical trials, ultimately aiming to offer patients a more effective and user-friendly approach to blood glucose monitoring. The prevailing market response and clinical achievements suggest a positive outlook for GlucoTrack’s future endeavors in diabetes care.

Related news for (GCTK)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.